GRAIL (GRAL) said Monday the first patient has been tested for eligibility with the company's investigational lung cancer ctDNA blood-based test in a phase 3 trial assessing adjuvant treatment regimens in people with non-small cell lung cancer.
The trial, which is sponsored by AstraZeneca (AZN) in collaboration with Daiichi Sankyo, uses GRAIL's targeted methylation platform to detect ctDNA, GRAIL said.
People will be screened with the GRAIL assay before surgery to assess eligibility for post-surgery randomization to an adjuvant treatment regimen, the company said.
Price: 15.53, Change: -0.39, Percent Change: -2.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.